ConductScience.org, home
A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus
API referenceFor AI assistants

Trial · NCT03379675

Results by group423

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 423

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Area Under the Respiratory Syncytial Virus (RSV) Viral Load (VL)-Time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 3Treatment A: JNJ-53718678 500 mg207.3Standard Deviation 89.55Log10 copies*hr/mL
Area Under the Respiratory Syncytial Virus (RSV) Viral Load (VL)-Time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 3Treatment B: JNJ-53718678 80 mg + Placebo246.3Standard Deviation 67.39Log10 copies*hr/mL
Area Under the Respiratory Syncytial Virus (RSV) Viral Load (VL)-Time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 3Treatment C: Placebo203.4Standard Deviation 87.63Log10 copies*hr/mL
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 5Treatment A: JNJ-53718678 500 mg344.5Standard Deviation 189.40Log10 copies*hr/mL
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 5Treatment B: JNJ-53718678 80 mg + Placebo424.2Standard Deviation 145.73Log10 copies*hr/mL
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 5Treatment C: Placebo340.4Standard Deviation 148.30Log10 copies*hr/mL
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 8Treatment A: JNJ-53718678 500 mg470.7Standard Deviation 305.38Log10 copies*hr/mL
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 8Treatment B: JNJ-53718678 80 mg + Placebo612.3Standard Deviation 253.29Log10 copies*hr/mL
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 8Treatment C: Placebo486.1Standard Deviation 254.15Log10 copies*hr/mL
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 14Treatment A: JNJ-53718678 500 mg534.4Standard Deviation 379.92Log10 copies*hr/mL
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 14Treatment B: JNJ-53718678 80 mg + Placebo747.1Standard Deviation 352.25Log10 copies*hr/mL
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 14Treatment C: Placebo619.9Standard Deviation 394.15Log10 copies*hr/mL
Change From Baseline in RSV Viral Load at Day 3Treatment A: JNJ-53718678 500 mg-2.210Standard Deviation 1.7185Log10 copies/mL
Change From Baseline in RSV Viral Load at Day 3Treatment B: JNJ-53718678 80 mg + Placebo-1.436Standard Deviation 1.6165Log10 copies/mL
Change From Baseline in RSV Viral Load at Day 3Treatment C: Placebo-2.221Standard Deviation 1.7093Log10 copies/mL
Change From Baseline in RSV Viral Load at Day 5Treatment A: JNJ-53718678 500 mg-3.156Standard Deviation 2.2887Log10 copies/mL
Change From Baseline in RSV Viral Load at Day 5Treatment B: JNJ-53718678 80 mg + Placebo-2.324Standard Deviation 1.6727Log10 copies/mL
Change From Baseline in RSV Viral Load at Day 5Treatment C: Placebo-3.031Standard Deviation 1.5010Log10 copies/mL
Change From Baseline in RSV Viral Load at Day 8Treatment A: JNJ-53718678 500 mg-4.960Standard Deviation 1.7804Log10 copies/mL
Change From Baseline in RSV Viral Load at Day 8Treatment B: JNJ-53718678 80 mg + Placebo-3.983Standard Deviation 1.3928Log10 copies/mL

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03379675/results

API referenceFor AI assistants